Janus Henderson Group’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Janus Henderson Group's GLUE Position: Q3 2026 in Review
Janus Henderson Group reduced its Monte Rosa Therapeutics (GLUE) stake by 98% in Q3 2026, selling an estimated $18M and leaving 24,915 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.
Janus Henderson Group first reported a position in GLUE in Q2 2023 and has held it in 5 quarters since. The position peaked at $26M in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Janus Henderson Group held 24,915 shares of Monte Rosa Therapeutics worth $297K as of Q3 2026.
- Janus Henderson Group sold 1,047,579 Monte Rosa Therapeutics shares in Q3 2026, an estimated $18M.
- Monte Rosa Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q3 2026, its #2310 holding.
- Janus Henderson Group first reported a position in Monte Rosa Therapeutics in Q2 2023 and has held it in 5 quarters since.
- Janus Henderson Group's Monte Rosa Therapeutics position peaked at $26M in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.